Inovio Pharmaceuticals Inc
Research Inovio Pharmaceuticals Inc (INO) on Bullrun: market cap USD 106.22M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 106.22M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 19.68M
- Free cash flow-USD 21.59M
Valuation Snapshot
latest market cap is USD 106.22M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 65.34K | -USD 85.00M | -USD 88.92M | n/a | -1.81 | USD 44.27M | USD 9.37M | USD 24.10M |
| FY2024 | USD 217.76K | -USD 107.00M | -USD 104.56M | n/a | -3.95 | USD 65.81M | USD 11.87M | USD 68.50M |
| FY2023 | USD 832.01K | -USD 135.00M | -USD 124.69M | n/a | -6.09 | USD 14.31M | USD 30.21M | USD 117.35M |
| FY2022 | USD 10.26M | -USD 279.82M | -USD 217.18M | n/a | -14.07 | USD 46.33M | USD 33.31M | USD 222.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 106.22M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 120.05M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 66.06M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 139.22M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 389.20M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.08B | n/a | n/a | n/a |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Inovio Pharmaceuticals Inc's market cap?
Inovio Pharmaceuticals Inc's market capitalization is USD 106.22M.
What does Inovio Pharmaceuticals Inc do?
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial.